Navigation Links
PacifiCare Capitulates to Latest Patient Revolt
Date:3/25/2008

Insurer authorizes cancer treatment for 17-year-old Nick Colombo, following online activism and in face of protest at office by friends, family, nurses

CYPRESS, Calif., March 25 /PRNewswire/ -- In the face of a national campaign on behalf of Nick Colombo, insurance giant PacifiCare has reversed its decisions and agreed to critically needed cancer treatments for the 17-year-old from Placentia, Calif. The decision came after the company was overwhelmed by calls organized by Nick's friends and family, along with RNs from the California Nurses Association/National Nurses Organizing Committee, and netroots activists.

Over 100 of Nick's classmates, friends of the family with their young children, and nurses protested in front of the insurance company headquarters this morning to demand that the approval be put in writing, which a PacifiCare representative, surrounded by T.V. cameras, and promised to do.

"I am extremely happy about PacifiCare's reversal," said Ricky Colombo, Nick's 19-year old brother. "The goal was to get treatment for Nick, and CNA/NNOC and other allies helped us with that. We decided to go through with the rally in order to get their decision on the record and make sure they back up their words -- and also because there are thousands of others in similar situations who can't get the care they need. We feel blessed to have this community supporting our family."

This is the latest example of a "patient revolt," where friends, family, and healthcare activists demand treatments denied by for-profit insurance corporations. In this case, Nick's physicians pleaded with PacifiCare to approve a cancer treatment, only to be overruled by an insurance company medical reviewer. PacifiCare is owned by United Health, the nation's largest health insurer, and just last year was fined $3.5 million by the state of California for wrongly denying 133,000 cases in a two-year period.

Inspired by the pleas of Nick's 19-year-old brother Ric
'/>"/>

SOURCE California Nurses Association
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Renovo Announces Results of Latest Phase 2 Studies of JUVISTA(R) (Human Recombinant TGFbeta3)
2. 49th Annual Meeting of the American Society of Hematology Will Feature the Latest Research in Blood Diseases
3. Digital Healthcare Announces Cincinnati Eye Institute is Latest Retasure Reading Center
4. UD researchers race ahead with latest spintronics achievement
5. Varian Medical Systems Exhibits Latest Technologies and Products Designed to Improve Speed and Precision of Radiotherapy at ESTRO 2007
6. Schiller AG Adopts Masimo Rainbow SET as Their Technology Platform of Choice for Patient Monitoring Devices Worldwide
7. Patient-Reported Outcomes (PROs) Improve Cancer Treatment -- Experts Agree
8. Baxter Announces FDA Approval of ARTISS Slow-Setting Fibrin Sealant in Treatment of Burn Patients
9. AstraZenecas Zactima to Earn Almost Five Percent Patient Share in the Treatment of Non-Small-Cell Lung Cancer by 2016
10. LUMEDX Updates Real-Time Patient and Resource Scheduler for Healthcare Systems
11. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...RK, Nov. 30 The Michael... today announced $1.5 million in total awards to s...isease-modifying therapies for Parkinson,s disease...hes to Drug Discovery for Parkinson,s Disease pro...on, plc (NYSE: ELN ), a neuroscience-based biote...
(Date:11/30/2009)...STERDAM, November 30 Biopharmaceut...e first patients have been enrolled in its,multina...The study is,designed to show reduction in transpl...ng an allogeneic stem cell transplantation with a ... patients eligible for an allogeneic,stem cell tra...
(Date:11/30/2009)...LLE, Md., Nov. 30 Novava...mpleted enrollment in the Phase II clinical study ...ommended strains) VLP vaccine candidate in healthy...This randomized, double-blind, active-controlled s...unogenicity of two different doses (15 mcg and 60 ...
(Date:11/30/2009)...EATTLE, Nov. 30 Cell The...nced today that its new class of platinum-based an...rated a stronger anti-tumor potency and activity c...ounds as well as the ability to overcome cisplatin...e presented in a paper titled "Novel Bis-platinum ...
Breaking Biology Technology:The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 2The Michael J. Fox Foundation Announces $1.5 Million in Funding to Advance Development of Drug Targets for Disease-Modifying Parkinson's Disease Treatments 3Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 2NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 3NOVAVAX Completes Enrollment in Phase IIa Study of Seasonal Influenza Vaccine in Older Adults 4New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 2New Class of Platinum-Based Anti-Tumor Drugs, Bisplatinates, Demonstrates Potent Anti-Tumor Activity and Ability to Overcome Resistance to Currently Available Platinum-Based Agents 3
...ED FOR TUESDAY, OCTOBER 28, SAN DIEGO, Oct. 22 N...ced today that the Company will report its third,q...ket closes on Tuesday,October 28, 2008. Neurocrine...iscuss its financial results and provide a Company...0 p.m. Eastern Time (2:00 p.m. Pacific,Time)., Pa...
...Inc.,(Nasdaq: TELK ) announced that its 2008 thir... on Wednesday, November 5, 2008 at 4:30 p.m. Easte...ease earlier that day of the,company,s financial r...008., The conference call will be accessible via ...lephone at 800-398-9367 or 612-332-7517. An,archiv...
...r Systems, Inc., a,medical device company developi... announced today that it has signed an agreement w...ercialize StemCor,s proprietary System,for the har...com/cgi-bin/prnh/20071030/STEMCORSYSTEMSLOGO ), S...spira will manage,the clinical trial program, lead...
Other Biology Technology:Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 2StemCor Signs Agreement With Hospira to Market New Medical Device to Oncologists and Hematologists 3
(Date:11/26/2009)...ers, red deer have been caught in the hunters, sig... more than decorative. They are lethal weapons tha... from The University of York, UK, has been intrigu...alf a century and has become fascinated by the mec...ng collaboration with Tomas Landete-Castillejos at...
(Date:11/26/2009)...phylococcus Aureus ) and other drug-resistant bact...asma prototype devices have been developed to offe...ktails. , Two prototype devices have been develo...n (e.g. hands and feet) in hospitals and public sp...another to shoot bacteria-killing agents into infe...
(Date:11/25/2009)... Cell Death Research Laboratory in the University ... the prestigious Johnson & Johnson Focused Funding...in cell damage in Parkinson,s disease. The award, ...t of innovation and excellence in science, was ann...his month at an event at the Hyatt Regency Hotel i...
Breaking Biology News(10 mins):Tough yet stiff deer antler is materials scientist's dream 2Plasma produces KO cocktail for MRSA 2Plasma produces KO cocktail for MRSA 3Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinson's 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 1New Media Led Effort Responds to AIDS Crisis in Black America 50086 2New Media Led Effort Responds to AIDS Crisis in Black America 50086 3New Media Led Effort Responds to AIDS Crisis in Black America 50086 4New Media Led Effort Responds to AIDS Crisis in Black America 50086 5New Media Led Effort Responds to AIDS Crisis in Black America 50086 6Abused Kids Face Higher Cancer Risk 50083 1Abused Kids Face Higher Cancer Risk 50083 2U M study finds voice box can be preserved even with the largest cancers 50080 1U M study finds voice box can be preserved even with the largest cancers 50080 2
...gy infrastructure for researching and developing n...e industry hundreds of millions of dollars annuall... the National Institute of Standards and Technolog...T, the studys authors found that over the last two...ted from small-molecule chemicals to large-molecul...
...archers contributed to a national effort to sequen...hat will help advance research in a broad range of... to understanding a variety of human diseases. , ...ectionately as Chlamy, has long fascinated scienti...s that retains characteristics of both. Like green...
...greatly improves the ability to separate global wa...e gas is prepared for use, according to engineers ...yzed the new plastics performance. , Like a spong...astic permits carbon dioxide or other small molecu...t, while impeding natural gas (methane) movement t...
Other Biology News:Biopharmaceutical infrastructure key to lower drug development costs 2'Chlamy' genome holds clues for renewable energy, the environment and human health 2New membrane strips carbon dioxide from natural gas faster and better 2New membrane strips carbon dioxide from natural gas faster and better 3
Goat Anti-Human SCP3 / SYCP3 Affinity Purified Polyclonal Antibody, Unconjugated from R&D Systems
Rabbit Anti-Human ADH5 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
Mouse Anti-Human Rad1 Monoclonal Antibody, Unconjugated, Clone 33 from R&D Systems
Cytological Nuclear Counterstain Kit - DAPI/SYTOX Green/PI - 300 slides from Molecular Probes (Invitrogen)
Biology Products: